AzTrials
AzTrials

Li-Fraumeni SyndromeReLFNCT04982744

Registry of Li Fraumeni and Li Fraumeni Like Syndromes

An observational study of Li-Fraumeni Syndrome and Li-Fraumeni-Like Syndrome, run by Istituto Ortopedico Rizzoli at 2 sites in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

ReLF is a retrospective and prospective registry, finalized for care and research purposes. It is articulated in main sections - strongly related and mutually dependent on each other - corresponding to different data domains: personal information, clinical data, genetic data, genealogical data, surgeries, etc. Read more about this study

Who is it for?
Any age
How many people
200 participants
Where
2 sitesItaly
Study dates
2 Jul 2020to Jul 2045
How long will I take part?
10 Years
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Child, Adult, Older adult

Study population: Patients affected by Li Fraumeni or Li Fraumeni Like syndromes

Who may be able to join

  • All patients affected by Li Fraumeni or Li Fraumeni Like syndromes

Who cannot join

  • Any condition unrelated to Li Fraumeni or Li Fraumeni Like syndromes

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Italy2 sites, 2 recruiting
  • Irccs Istituto Ortopedico Rizzoli

    Bologna, Emilia-Romagna, 40136

    Marina Mordenti, PhD, +39 051 6366062, registri.malattierare@ior.it

    Marcella Lanza, PhD, +39 051 6366169, registri.malattierare@ior.it

    Recruiting
  • IRCCS Istituto Ortopedico Rizzoli

    Bologna, Emilia-Romagna, 40136

    Enrolling by invitation

Other trials in Italy

About this study

Official title: Registry of Li Fraumeni and Li Fraumeni Like Syndromes That Collects Clinical, Functional, Genetic, Genealogical, Imaging, Surgical, Treatment, Quality of Life Data. Data is Linked to Patients' Biological Samples, When Available

ReLF is a retrospective and prospective registry, finalized for care and research purposes. It is articulated in main sections - strongly related and mutually dependent on each other - corresponding to different data domains: personal information, clinical data, genetic data, genealogical data, surgeries, etc. This approach has been developed to corroborate and integrate data from different resources and aspects of the diseases and to correlate genetic background and phenotypic outcomes, in order to better investigate diseases pathophysiology. Due to legal requirements, institutional directives and organizational issues, we are unable to include individuals residing outside Italy in the registry at this time. We are currently engaged in the preparation of a recruitment process for individuals residing outside Italy.

Read the detailed description

The traditional method of collecting patient information is often chaotic, inconvenient, and sometimes even unsafe, particularly when dealing with rare diseases. In 2020, the need to simplify the diagnostic process and to overcome the difficulties of data storage and analysis, led to the suggestion of implementing the Registry of Li Fraumeni and Li Fraumeni Like syndromes (ReLF).

The ReLF relies on an IT Platform named GeDI (Genotype-phenotype Data Integration platform). This solution, realized by a collaboration among Department of Rare Skeletal Disorders and a local software-house (Dilaxia Spa), is a GDPR-compliant, multi-client, web-accessible system and it has been designed according to current medical informatics standards (Orphacode, ICD-10, Human Genome Variants Society, Findability Accessibility Interoperability Reusability -FAIR- Principles). GeDI is continuously implemented to improve management of persons with Li Fraumeni and Li Fraumeni Like Syndromes and to help researchers in analyzing collected information. ReLF is articulated in main sections:

  • Personal data: it comprises general information, birth details and residence data;
  • Patient data: including the patients internal code, the hospital code and other patient details;
  • Diagnostic Process: the diagnosis, the status (affected, suspected, etc.), age at diagnosis, comorbidities, allergies, etc.;
  • Genogram: a tool for designing the family transmission of the disease, alongside information on the disease status of all relatives included;
  • Clinical events: it records a long list of signs and symptoms as well as several additional items to describe the disease
  • Genetic Analysis and Alteration: including analytical technique, sample information, analysis duration, etc. This section also comprises detailed information on any detected pathological variants (e.g. gene, international reference, DNA change, protein change, genomic position, etc.);
  • Visits: this section includes visit type (genetic, orthopedic, rehabilitation, pediatric, etc.), the date of the visit, prescriptions, imaging, etc.;
  • Treatments: this section comprises information of a wide range of treatments including pharmacological, devices, supplements, and other treatments such as psychological, nutritional, etc.;
  • Surgeries: this section contains information on the type of surgeries, the age of the patients, the site/localization of the procedures, etc.
  • Documents: this repository allow us to store all types of documents (radiological reports, imaging, consents, clinical reports, etc.);
  • Consents: this section provides a comprehensive overview of all consents collected, including the collection date;
  • Samples: this section includes information on the samples, like the type, date of collection, etc.
  • PROs: this section collects information on patients reported outcomes such as the quality of life or ABC scale.
Keywords
Disease Registry, Natural History Study, Genotype-Phenotype Correlation, Disease Evolution
Medical subject headings
Li-Fraumeni Syndrome, Li-Fraumeni-Like Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04982744
Study groupRoleWhat they receive
Patients affected by Li Fraumeni and Li Fraumeni Like syndromesThe group comprises all patients affected by Li Fraumeni and Li Fraumeni Like syndromes

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Natural History and Epidemiology

    Assessment of epidemiological information. Anthropometric data: weight in kg, height in cm. In addition, weight and height will be combined to report BMI as kg/m^2 Clinical details of the tumor: site of the lesion, number of recurrence(s), presence/absence of metastasis, size of lesion in cm^3 Additional clinical data: type of surgery, age at surgery in years are updated at each follow up and retrospectively (when possible).

    Clinical reports, medical charts and imaging are the primary source of data.

    Measured: Since the disease is rare, the timeframe is strictly related to patients enrolment and consequently to amount of collected data. Considering the low prevalence of this disease, the time frame is up to 10 years.

Secondary outcomes (1)
  1. Genotype-Phenotype Correlation

    The secondary outcome comprises the correlation between genotype and phenotype. This includes, but is not limited to, clinical features and genetic background. This will be pursued using the information collected during visits and follow-ups and the genetic information resulting from molecular investigations.

    Collection of genetics background (target gene, type of mutation, clinical significance are reported following HGVS nomenclature) and family history (in terms of inheritance by maternal or paternal line).

    Anthropometric data (weight in kg, height in cm. In addition, weight and height will be combined to report BMI in kg/m^2), clinical details (site of the lesion, recurrence, metastasis), orthopedic and functional features are updated at each follow up.

    Measured: The timeframe is strictly related to patients enrolment and consequently to amount of collected data. Considering the low prevalence of this disease, the time frame is up to 10 years.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jul 2021
  2. Study start2 Jul 2020
  3. Primary completionJul 2030 (estimated)
  4. Study completionJul 2045 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Other
Enrolment
200 participants (estimated)
Target duration
10 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT04982744
Sponsor's protocol ID
579/2020/Oss/IOR
Acronym
ReLF
Status last verified
Nov 2025
First submitted
30 Jun 2021
Last updated
20 Nov 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in